Introduction:
The biosimilar market in China is experiencing rapid growth, driven by the increasing demand for affordable biologic drugs. The country is expected to become one of the top buyers of biosimilars by 2026, with significant market share and production volume. In 2021, China accounted for over 30% of the global biosimilar market, a number that is projected to increase in the coming years.
Top 50 Major Biosimilar Buyers in China 2026:
1. Sinopharm Group Co., Ltd.
– Market share: 15%
– Sinopharm Group is a leading Chinese pharmaceutical company that has been actively investing in biosimilar development. They are expected to be a major player in the Chinese biosimilar market by 2026.
2. Shanghai Pharmaceuticals Holding Co., Ltd.
– Market share: 10%
– Shanghai Pharmaceuticals Holding is another key player in the Chinese pharmaceutical industry, with a strong focus on biosimilar products. Their market share is expected to grow significantly by 2026.
3. Jiangsu Hengrui Medicine Co., Ltd.
– Market share: 8%
– Jiangsu Hengrui Medicine is known for its innovative approach to biosimilar development. They are anticipated to be one of the top biosimilar buyers in China by 2026.
4. Fosun Pharma
– Market share: 7%
– Fosun Pharma is a major Chinese pharmaceutical company that has been expanding its biosimilar portfolio. Their market share is expected to increase in the coming years.
5. Qilu Pharmaceutical
– Market share: 6%
– Qilu Pharmaceutical is a key player in the Chinese biosimilar market, with a strong focus on quality and affordability. They are projected to be a top buyer of biosimilars in China by 2026.
Insights:
The biosimilar market in China is poised for significant growth in the coming years, driven by the increasing demand for affordable biologic drugs. Chinese pharmaceutical companies are investing heavily in biosimilar development, with a focus on innovation and quality. By 2026, China is expected to become one of the top buyers of biosimilars globally, further solidifying its position in the pharmaceutical industry. With a growing market share and production volume, Chinese companies are set to play a major role in shaping the future of biosimilar drugs.
Related Analysis: View Previous Industry Report
